Emerging studies suggest Retatru tide , a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a significant development for obesity treatment. Early clinical trials have shown substantial decreases in abdominal mass , potentially outperforming other weight-loss medications . Despite this, more st